COR170

Very selective synthetic CB2 antagonist or inverse agonist, reserved for research.

C₃₁H₃₆N₂O₂

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

Data sheet

Names

IUPAC name: N-(1-adamantyl)-4-oxo-1-pentyl-6-phenylquinoline-3-carboxamide
Other names: COR 170 · COR-170

Identifiers

Formula: C₃₁H₃₆N₂O₂
Molar mass: 468.60 g/mol
PubChem CID: 25033736(new tab)
InChIKey: MSJISJDTJJYBFT-UHFFFAOYSA-N

Class

Family: ECS modulator (research)

Legal status

Status: Unscheduled

See the legal framework

Updated on 13 October 2026

Receptors and activity

CB2Inverse agonist88 out of 100
Ki 3,8 nM sur le CB2 ; Ki supérieur à 10 000 nM sur le CB1 (Pasquini et coll., 2008 ; ChEMBL)

Bar length shows the relative strength of the interaction, as an indication.

Subjective signature

Calm: 5 out of 100; Relaxation of body and mind; reduced mental noise without marked drowsiness.
Clarity: 2 out of 100; Sustained attention and clear thinking; functional lucidity, not euphoria.
High: 2 out of 100; Euphoria and sensory intensity; altered perception of time and space.
Appetite: 2 out of 100; Stimulation of hunger and of taste appreciation (the “munchies” effect).
Sleep: 2 out of 100; Sedative effect: aids sleep onset and the continuity of deep sleep.

Editorial estimate, not clinical.

Pharmacology

COR170 is a synthetic quinolone-3-carboxamide, systematic name N-(1-adamantyl)-4-oxo-1-pentyl-6-phenylquinoline-3-carboxamide, whose structure is registered under this code in PubChem (CID 25033736). Its affinity for the CB2 receptor is a Ki of 3.8 nM, against more than 10 000 nM for CB1 (Pasquini et al., 2008; ChEMBL). The studies that use the code COR170 describe it as a CB2 antagonist or inverse agonist: at 1 nM, it abolishes the effects of COR167, a related CB2 agonist, on glutamate and LDH release from rat brain cortical slices (Contartese et al., 2012), and at 10 µM, alone, it reduces IL-6 production by synovial fibroblasts from patients with rheumatoid arthritis (Lowin et al., 2016). The publications cited name the molecule only by its code: the match with this structure rests on PubChem and ChEMBL. COR167 carries an isopropyl group at position 6 and is a different molecule (Borgonetti et al., 2023). No published human data has been found.

Key sources.

History

Source: Fully synthetic molecule, from the 4-quinolone-3-carboxamide series developed at the University of Siena (Italy) by the team of F. Corelli and S. Pasquini (Pasquini et al., 2008). No source consulted describes its presence in a plant.

Origin (research tool)

No biosynthetic pathway: a chemically synthesised molecule, obtained by the methods of amide chemistry applied to the 4-quinolone-3-carboxamide series.

Legal framework

European Union: No harmonised control measure at European Union level has been identified in the sources consulted. Any control therefore falls under the national legislation of the Member States.
France: COR170 is not named in any annex of the French narcotics list (ANSM consolidated list, updated 16 February 2026). Its structure, a 4-quinolone-3-carboxamide, meets none of the family definitions of that list: they target derivatives of indole, indazole, pyrrole, pyrrolo[3,2-c]pyridine or thiazole, cyclohexylphenols and the benzo[c]chromene nucleus, and none covers the 4-quinolone. It is therefore not captured and remains unscheduled in France, which does not mean that its sale or use is authorised.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

References

Structured data

SMILES: CCCCCN1C=C(C(=O)C2=C1C=CC(=C2)C3=CC=CC=C3)C(=O)NC45CC6CC(C4)CC(C6)C5
InChIKey: MSJISJDTJJYBFT-UHFFFAOYSA-N

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.